Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ajt.15941 http://scihub22266oqcxt.onion/10.1111/ajt.15941 32330343!7264777!32330343     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Transplant 2020 ; 20 (7): 1800-1808 Nephropedia Template TP {{tp|p=32330343|t=2020. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter |pdf=|usr=}}{{32330343}} gab.com Text COVID-19 in solid organ transplant recipients: Initial report from the US epicenter JO: Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32330343 #FOAvip Solid organ transplant recipients may be at a high risk for SARS-CoV-2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV-2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). Ninety patients were analyzed with a median age of 57 years. Forty-six were kidney recipients, 17 lung, 13 liver, 9 heart, and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%), and dyspnea (43%). Twenty-two (24%) had mild, 41 (46%) moderate, and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab, and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients. Twit Text FOAVip COVID-19 in solid organ transplant recipients: Initial report from the US epicenter ????Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32330343 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32330343 #FOAvip English Wikipedia <ref>{{Cite pmid|32330343}}</ref> COVID-19 in solid organ transplant recipients: Initial report from the US epicenter #MMPMID32330343 Pereira MR; Mohan S; Cohen DJ; Husain SA; Dube GK; Ratner LE; Arcasoy S; Aversa MM; Benvenuto LJ; Dadhania DM; Kapur S; Dove LM; Brown RS Jr; Rosenblatt RE; Samstein B; Uriel N; Farr MA; Satlin M; Small CB; Walsh TJ; Kodiyanplakkal RP; Miko BA; Aaron JG; Tsapepas DS; Emond JC; Verna EC Am J Transplant 2020[Jul]; 20 (7): 1800-1808 PMID32330343show ga Solid organ transplant recipients may be at a high risk for SARS-CoV-2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV-2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). Ninety patients were analyzed with a median age of 57 years. Forty-six were kidney recipients, 17 lung, 13 liver, 9 heart, and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%), and dyspnea (43%). Twenty-two (24%) had mild, 41 (46%) moderate, and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab, and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients. |*Transplant Recipients[MESH] |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Adult[MESH] |Aged[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |Azithromycin/therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*complications/drug therapy/*epidemiology/mortality[MESH] |Critical Care[MESH] |Female[MESH] |Hospitalization[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Immunosuppression Therapy[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Intensive Care Units[MESH] |Intubation[MESH] |Male[MESH] |Middle Aged[MESH] |New York City/epidemiology[MESH] |Organ Transplantation/*adverse effects[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/*epidemiology/mortality[MESH] |Respiration, Artificial[MESH] |SARS-CoV-2[MESH] |Steroids/therapeutic use[MESH] |Treatment Outcome[MESH]COVID-19 in solid organ transplant recipients: Initial report from the(epmc).pdf DeepDyve Pubget Overpricing